Cover Image
市場調查報告書

5-羥色胺受體6 (5-HT6,血清素受體6,HTR6) - 開發中產品分析

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 358699
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
Back to Top
5-羥色胺受體6 (5-HT6,血清素受體6,HTR6) - 開發中產品分析 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H2 2016
出版日期: 2016年09月21日 內容資訊: 英文 87 Pages
簡介

5-HT6受體是5-HT受體的亞型,與內因性神經傳達物質血清素結合。5-HT6受體在老年癡呆症和其他類型的癡呆症、肥胖中都扮演著重要的角色。

本報告提供5-羥色胺受體6 (5-HT6,血清素受體6,HTR6)的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品
  • 階段不明的產品

開發中的產品:各企業

開發中的產品:各大學/研究機關

治療藥的評估

  • 單劑/聯合治療別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Adamed Sp. z o.o.
  • Avineuro Pharmaceuticals, Inc.
  • Axovant Sciences Ltd.
  • Biotie Therapies Corp.
  • Galenea Corp.
  • H. Lundbeck A/S
  • Reviva Pharmaceuticals Inc.
  • Suven Life Sciences Ltd.
  • Teva Pharmaceutical Industries Ltd.

藥物簡介

暫停的計劃

開發中止的產品

最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0533TDB

Summary

Global Markets Direct's, '5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H2 2016', provides in depth analysis on 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted pipeline therapeutics.

The report provides comprehensive information on the 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)
  • The report reviews 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics and enlists all their major and minor projects
  • The report assesses 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) Overview
  • Therapeutics Development
    • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Products under Development by Stage of Development
    • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Products under Development by Therapy Area
    • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Products under Development by Indication
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Products under Development by Companies
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Products under Development by Universities/Institutes
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Companies Involved in Therapeutics Development
    • Adamed Sp. z o.o.
    • Avineuro Pharmaceuticals, Inc.
    • Axovant Sciences Ltd.
    • Biotie Therapies Corp.
    • Celon Pharma Sp. z o.o.
    • Galenea Corp.
    • H. Lundbeck A/S
    • Reviva Pharmaceuticals Inc.
    • Suven Life Sciences Ltd.
    • Teva Pharmaceutical Industries Ltd.
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Drug Profiles
    • ADN-1184 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADN-2013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADN-3662 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AV-3208 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVN-0189 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVN-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVN-211 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVN-3085 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVN-3205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVN-322 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • idalopirdine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • intepirdine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • landipirdine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LuAF-35700 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RP-5063 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 1 to Antagonize 5-HT6 Receptor for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 2 to Antagonize 5-HT6 for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize 5-HT 6 and 5-HT2A for Behavioral and Psychological Symptoms of Dementia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize 5-HT6 for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize 5-HT6 Receptor for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize 5-HT6 Receptors for Cognitive Impairment - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target 5-HT2C and 5-HT6 Receptor for Schizophrenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVN-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVN-502 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVN-507 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVN-512 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Dormant Projects
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Discontinued Products
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Featured News & Press Releases
    • Jul 07, 2016: Idalopirdine granted Fast Track Designation by U.S. Food and Drug Administration (FDA)
    • May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016
    • Apr 21, 2016: FAU site for first US clinical trial for Lewy Body dementia
    • Apr 11, 2016: Lundbeck to Present Data on Idalopirdine at American Academy of Neurology
    • Mar 11, 2016: Lundbeck starts clinical phase III program with Lu AF35700 in patients with treatment resistant schizophrenia
    • Feb 09, 2016: Axovant Sciences Announces Launch Of First-In-Class Clinical Programs Of RVT-101 For Lewy Body Dementia
    • Dec 07, 2015: Suven Initiates Phase 2A trial of SUVN-502 in USA in Alzheimer's Disease
    • Oct 28, 2015: Axovant Sciences Announces RVT-101 Presentations At The Clinical Trials In Alzheimer's Disease Meeting
    • Oct 22, 2015: Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits
    • Oct 06, 2015: Axovant Sciences Announces Start Of Confirmatory Phase 3 MINDSET Study And Special Protocol Assessment Agreement With FDA
    • Jul 22, 2015: Axovant's RVT-101 Phase 2b Completer Analysis Demonstrates Statistically Significant Benefits in Cognition and Function Through 48 Weeks
    • Jul 01, 2015: Avineuro Completed Phase II Clinical Study Of AVN-211, A Selective 5-HT6 Receptor Antagonist
    • Jun 29, 2015: Axovant Sciences To Present RVT-101 Alzheimer's Disease Clinical Data At AAIC 2015 Meeting
    • Dec 23, 2014: Biotie Announces Start Of Syn120 Phase 2A Trial In Parkinson's Disease Dementia And Provides Outlook Update For Near Term Pipeline Events
    • Sep 08, 2014: Suven Life Sciences Provides Update On Its Molecule For Alzheimer's Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Adamed Sp. z o.o., H2 2016
  • Pipeline by Avineuro Pharmaceuticals, Inc., H2 2016
  • Pipeline by Axovant Sciences Ltd., H2 2016
  • Pipeline by Biotie Therapies Corp., H2 2016
  • Pipeline by Celon Pharma Sp. z o.o., H2 2016
  • Pipeline by Galenea Corp., H2 2016
  • Pipeline by H. Lundbeck A/S, H2 2016
  • Pipeline by Reviva Pharmaceuticals Inc., H2 2016
  • Pipeline by Suven Life Sciences Ltd., H2 2016
  • Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Dormant Projects (Contd..2), H2 2016
  • Dormant Projects (Contd..3), H2 2016
  • Dormant Projects (Contd..4), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top